Staff testing in care homes for older people: policy implications for early stages of future pandemic responses

Lily O'Brien[1], Oliver Stirrup[2], Catherine Henderson[3], James Blackstone[4], Natalie Adams [5], Borscha Azmi [5], Lavinia Bertini

[6], Jackie Cassell[6], Dorina Cadar [7], Andrew Copas[2], Christopher Finn McQuaid[1], Paul Flowers [8], Laura Shallcross[5], Lara

Goscé[1,2]

[1]Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

[2]Institute for Global Health, UCL, London, UK

[3]Care Policy and Evaluation Centre, London School of Economics and Political Science, UK

[4]Clinical Trials Unit, University College London, London, UK

[5]Institute of Health Informatics, Faculty of Pop Health Sciences, UCL, London, UK

[6]Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK

[7]CEDAR Lab, Centre for Dementia Studies, Department of Clinical Neuroscience, Brighton and Sussex Medical School, Brighton, UK

[8]Department of Psychological Sciences & Health, University of Strathclyde, Glasgow, UK

Abstract

Background: Care home residents are at high risk of severe outcomes following respiratory infection due to age, co-morbidities, and close contact with staff and other residents. Frequent staff testing could potentially reduce respiratory infection cases in residents, but evidence is limited. This study uses historical COVID-19 data in England to assess the impact of varying staff testing rates under different transmission scenarios to inform response during future pandemics.

Methods: We developed a compartmental model of SARS-CoV-2 transmission in England, with three population strata: general population, care home staff, and residents. The model was calibrated using prevalence data from January 2021 to March 2022 and testing rates from the VIVALDI Study (ISRCTN14447421). We conducted a scenario analysis projecting resident cases and deaths over 12 months under varying staff testing frequencies (monthly, twice-monthly, weekly, twice-weekly, daily) assuming a new dominant strain. We also explored the impact of testing when combined with a hypothetical low-cost highly-effective public health and social measures.

Findings: Staff testing alone has little impact on reducing cases and deaths in the resident population. Daily testing could avert only 3.8% (95%UI: 3.1-4.4%) cases and 3.5% (95%UI: 2.3-4.4%) deaths compared to a baseline testing of less than one test per month. When combined with public health and social measures, however, the effect is large. Daily staff testing, combined with public health and social measures, can reduce resident cases by 54% (95%UI: 50-58%) and

deaths by 50% (95%UI: 26-59%). Additionally, if testing frequency is reduced but there is still a public health and social

measure, the effect size decreases, however there are potential cost savings (£0.7 to £3.4 million).

Interpretation: Increasing staff testing alone is insufficient to significantly reduce SARS-CoV-2 cases and deaths in care

home residents. However, combining testing with some form of a public health and social measure aimed at reducing

transmission among residents, is epidemiologically effective and cost-effective in most scenarios and possibly cost

saving.

Introduction

Over a quarter of a million individuals aged 65 and above live in care homes in England and Wales [1] with many affected by comorbidities that increase their risk of poor outcomes. Care homes face high risks of disease outbreaks due to several factors, including the challenges of social distancing in shared living spaces and communal areas, and frequent contact required between staff and residents for daily care. Between March 2020 and May 2021, 24.3% of deaths of care homes residents had been attributed to COVID-19 in England and Wales, with 42,341 total deaths involving COVID-19 being registered [2]. It is essential that care homes can function safely and efficiently during future pandemics to protect vulnerable residents and care home staff. COVID-19 vaccinations were made available to high-risk groups, including care home residents and staff, from December 2020 [2], providing protection against the virus. However, before the introduction of vaccines in England, care homes faced high cases and deaths amongst residents. This illustrates the importance of having robust policies and procedures in place to minimise disruptions to the care home sector; protecting vulnerable populations especially at the beginning of a new respiratory pandemic when pharmaceutical interventions may not be available yet.

While several studies have examined intervention strategies in care homes [3-5] the findings vary regarding the most effective approaches to minimising resident cases and deaths, with some studies recommending asymptomatic staff testing every 3 days [3] and others every 7 to 10 days [4]. Additionally, some research highlights the importance of

pharmaceutical interventions such as vaccination, illustrating its increased efficacy over staff testing [6] and others

emphasise the importance of other public health and social measures such as isolating positive cases [4], personal

protective equipment (PPE), improved ventilation and contact tracing. It is crucial to determine the best strategies for

outbreak control, while also understanding the associated economic costs and quality of life of residents, to guide policy

decisions in future pandemics.

In this study, we aim to assess possible testing policies to be adopted during future pandemics. To do so, we used

COVID-19 as a case study and developed a compartmental model simulating SARS-CoV-2 transmission in care homes in

England. While we modelled COVID-19, due to it being the latest pandemic and having available data, the model is

adaptable to similar respiratory infections and could be highly informative in future pandemics, including avian influenza

(in case of human-to-human transmission) or emerging mpox variants. The aim of our study is to provide evidence for

effective testing protocols that can enable early detection and infection control in vulnerable populations such as care

homes. We compared a baseline scenario with three intervention strategies to determine the optimal frequency of staff

testing and assess its effectiveness when combined with a public health and social measure. Additionally, we took

associated testing and hospitalisation costs into account and estimated the economic impact of these interventions in the

form of incremental costs per case averted.

Methods

Model Overview

We developed a compartmental model to simulate the transmission of SARS-CoV-2 in England, stratifying the population into three distinct groups: the general population, care home staff, and care home residents. The general population encompasses all individuals in England who are not classified as care home staff or residents, including all age groups. Care home staff are defined as individuals aged 18 and over who work in care homes in direct contact with residents, while care home residents are aged 65 and above. The model considers a cohort comprising 10,000 senior care home residents and estimated 13,350 staff members by calculating the ratio of staff and occupied beds (~1:1.3) from the VIVALDI Study (ISRCTN14447421) [7].

The Vivaldi-CT trial which informed this analysis began in January 2023 and was developed in close collaboration with care providers. Engagement events with a diverse range of care home staff and sector representatives helped shape the trial intervention "Test to Care", supporting twice-weekly LFD testing for COVID-19 in care homes. Discussions with care providers addressed the acceptability and uptake of testing and acted as a platform to raise concerns about potential implications for staff members and organisations involved in the trial. Feedback informed the testing protocol. However, due to lower than anticipated COVID-19 case numbers, the trial was stopped early. Here, we use mathematical modelling to simulate the original trial design and assess how it might perform in the early stages of a future pandemic.

A critical assumption of our model is that care homes operate at full capacity, with new residents replacing those who

have died. Because we want our model to be informative of the first stages of a new pandemic, we assume that residents

are unvaccinated and lack long-term immunity from previous infections. Additionally, to reflect the restriction in visitations

allowed at the beginning of the COVID-19 pandemic, we assume that while staff interact with the general population,

residents, and other staff, residents only interact with staff and fellow residents. Consequently, the primary routes of

SARS-CoV-2 ingress into the care home setting are via staff or new residents, excluding visitors or contractors. This

model thus reflects a pandemic scenario restricted to internal transmission within the care home environment. We based

this assumption on observations from the COVID-19 pandemic, during which contact between care homes and the

outside world was significantly restricted to mitigate transmission risks. We acknowledge however that these restrictions

may differ for future pandemics, which could affect the applicability of our findings.

The model, which employs a susceptible-exposed-infectious-recovered (SEIR) framework, was coded using R (v4.3.3)

and calibration was performed through the History Matching and Emulation (hmer) package [8-9]which uses Bayes Linear

emulation and history matching, The model was calibrated to observed COVID-19 prevalence rates in the general

population [10]and care home residents [7] between January 2021 and March 2022. Full parametrisation, as well as

model schematic, equations, and calibration, can be found in the supplementary document.

Following calibration, we split our model into a baseline scenario and different intervention scenarios, with testing rates

and the implementation of an additional public health and social measure differing between them. Due to new strains

differing in terms of infectiousness and mortality [11], the objective was to consider a new strain to inform policy making

for future pandemics. Therefore, we modelled a new hypothetical strain that is both more infectious and more deadly. We

then estimated resident cases and death for the following 12 months.

Intervention scenarios

We evaluated three intervention scenarios against a baseline, as shown in Table 1. The baseline scenario assumes that

staff members are tested less than once a month (~0.6), in order to represent a hypothetical baseline situation where only

symptomatic individuals are required to test. Intervention 1 scenarios, instead, consider the following five testing regimes:

(a) monthly, (b) twice a month, (c) once a week, (d) twice a week and (e) daily testing of all staff. In all scenarios, lateral

flow tests (LFT) for staff were assumed to have perfect sensitivity, meaning any positive result was treated as a true

positive, with staff immediately self-isolating until recovery. The model was designed to study a pandemic period, so we

also modelled two additional intervention scenarios that consider a hypothetical continuous public health and social

measure aimed at reducing infection transmission among residents. Intervention 2 considers baseline testing plus a public

health and social measure, while intervention 3 combines intervention 1 (the five testing regimens) and intervention 2 (the

public health and social measure). To estimate the maximum possible impact of staff testing, we assumed that this

hypothetical public health and social measure leads to no infection transmission among residents, whilst transmission

between staff and residents is possible. All interventions are described in Table 1.

Table 1: Intervention scenarios and description

Intervention scenario	Description
Baseline	Staff are tested less than once a month (~0.6 tests per month per staff member)
Intervention 1	Staff are tested either (a) once a month, (b) twice a month, (c) once a week, (d) twice a week or (e) daily
Intervention 2	Baseline testing with a public health and social measure

Intervention 3	Staff are tested either (a) once a month, (b) twice a month, (c) once a week, (d) twice a week or (e) daily, in conjunction with a public health and social measure

132   For every intervention, and testing frequency within the intervention, we calculated numbers of resident cases and deaths

133   observed and compared them to the baseline scenario estimating numbers of cases and deaths averted.

Health economic analysis

We associated testing costs and hospitalisation costs with the epidemiological modelling results. No costs are accounted

for the public health and social measure. Testing and hospitalisation costs were accounted for in each intervention

scenario (including baseline) and were associated to the modelling output 'cases averted', which differed depending on

the testing strategy and the inclusion of a hypothetical public health and social measure. Testing costs included LFT

costs, staff sick pay, and agency backfill. Staff sick pay and agency backfill costs were sourced from audit data provided

by the UCL Comprehensive Clinical Trials Unit (CCTU) collected during the VIVALDI-CT [12] factoring in the average

duration of staff absences. The unit costs for LFTs were obtained from the United Kingdom Health Security Agency

(UKHSA) [13]. LFT costs were multiplied by the total number of care home staff assumed in the model over a 12-month

period. As each scenario required different testing frequencies, the number of LFTs performed varied by the intervention

(e.g. in the case of monthly testing, 13,350 tests each month over a 12-month period are assumed to be performed). Staff

sick pay and agency backfill costs were calculated based on the number of staff self-isolating over the 12 months, which

also differed across intervention scenarios. The average cost per staff member (averaging over mean costs per home)

was *per episode* following a positive test. Only shifts that were reimbursed by UKHSA were counted. This was a sample

of 24 care homes representing 180 staff members with COVID-related sickness. These costs—sick pay, agency backfill,

and LFTs—were then combined to determine the total cost per intervention. All costs are reported in 2022-23 pounds (£).

Hospitalisation costs were calculated for each intervention and were divided into critical care and non-critical care costs.

Resident hospitalisations were estimated from our model output, by multiplying the number of individuals who become

infected with SARS-CoV-2 for each intervention, by the proportion of cases requiring either critical or non-critical care. As

the aim of this analysis is to estimate the cost-effectiveness of the aforementioned testing interventions during the first

stages of a new pandemic, the hospitalisation rates were based upon a report from Ferguson et al. (2020) [14] who

estimated the severity of COVID-19 cases by age-group during the first wave of the pandemic in England (however we

also acknowledge that in reality some residents requiring hospitalisation will not necessarily access these facilities).

Critical and non-critical care costs were obtained from the National Institute for Health and Care Excellence (2023)[15]. All

cost data is reported in the technical appendix. Due to the theoretical nature of interventions 2 and 3, we do not consider

public health and social measure associated costs, which may include costs such as increased cleaning, re-rostering of

staff, provisions of face masks, etc. and thus could not be included in this analysis.

Following this we performed a cost-effectiveness analysis by estimating the incremental cost of the interventions

(compared to baseline) over the number of cases averted. The ICER is shown below as incremental cost per case

averted:

164
$$\frac{C_{int} - C_{bas}}{N_{bas} - N_{int}}$$

165 Where C_{int} and N_{int} are respectively the cost and the number of cases incurred by one of the interventions, and C_{bas} and

166 N_{bas} are costs and cases at baseline.

167 Due to some interventions having ranges crossing zero, we also calculated the probabilities of these interventions being

168 cost saving. For every run of the model, we calculated how many were cost saving compared to the baseline.

Sensitivity analysis

170 To account for imperfect performance of the test, a sensitivity analysis was undertaken on the diagnostic sensitivity of the

171 LFTs and is described in the supplementary material. For each of the 803 model runs, a random value between 68% and

172 76% was selected to represent the estimated sensitivity of LFTs [16] . The proportion of resident cases and deaths, as

173 well as costs related to resident hospitalisation, staff testing, and quarantine, were then calculated.

Results

Fig 1 displays the percentage of resident cases and deaths averted compared to the baseline scenario over a 12-month

period, for each intervention. Modelling results show that testing alone (intervention 1) has limited epidemiological impact

in reducing cases and deaths. During the twelve-month run time, daily staff testing alone averted up to 3.8% (95%UI: 3.1-

4.5%) of resident cases and 3.5% (95%UI: 2.3-4.4%) of resident deaths compared to the baseline testing scenario.

Similarly, baseline testing with a public health and social measure (intervention 2) also showed limited impact, by reducing

up to 7.4% (95%UI: 5.7-9.2%) cases and 7.0% (95%UI: 5.2-9.0%) deaths compared to baseline testing alone.

Contrastingly, the two interventions combined led to a decrease of more than 20% in cases and deaths when testing of

staff was performed at least twice a week, with maximum impact of 53.6% (95%UI: 49.5-57.7%) cases and 49.9%

(95%UI: 26.3-59.1%) deaths averted by daily testing, when compared to baseline.

Fig 1: Percentage of cases and deaths averted for each intervention with 95% uncertainty interval (UI).

Intervention 1: Staff are tested once a month, twice a month, once a week, twice a week and daily. Intervention 2:

Baseline testing rates with a hypothetical public health and social measure that prevents the transmission of the infection

between residents. Intervention 3: Staff are tested once a month, twice a month, once a week, twice a week and daily, in

conjunction with the hypothetical public health and social measure. Increased staff testing alone is not enough to visibly

reduce the number of cases and deaths in the resident population compared to baseline. Similarly, a public health and

social measure alone has also a limited epidemiological impact. However, combining testing and public health and social

measures can lead to a ~20% reduction in cases and deaths, in the case of weekly testing, ~30% reduction with twice-

weekly testing, or up to ~60% reduction with daily testing.

Following the epidemiological analysis, total costs were calculated for each intervention over the whole 12-month

implementation period (Table 2) and associated with the model epidemiological results (Fig 1). The analysis shows that

testing-only strategies (intervention 1) are costly, with total incremental costs ranging from £0.6 to £22 million over a 12-

month period. In contrast, baseline, monthly or twice-a-month testing when combined with a hypothetical public health and

social measure (interventions 2, 3a, 3b) dominate the baseline strategy, leading to significant cost savings compared to

baseline testing without a public health and social measure, with savings ranging from £0.7 to £3.4 million. These savings

are attributed to a reduction in resident hospitalisations and no public health and social measure related implementation

costs. This means that the combined baseline/monthly/bi-monthly testing plus a public health and social measure strategy

would be cost-saving only in situations where the cost of implementing the public health and social measure was no

higher than £3.4 million. More frequent testing strategies, such as weekly and twice-a-week testing combined with public

health and social measures, may have less substantial cost savings than less frequent testing strategies, but are cost-

effective compared to baseline due to the larger number of cases averted, and have high probabilities of also being cost-

saving (96.6% and 89.4%, respectively); however, this depends on the cost of the public health and social measure. In

contrast, intervention 3 with daily testing is more expensive than baseline in most cases, but it may be cost-effective as it

leads to strong reductions in cases and deaths. Thus, any decision on its implementation is up to policy makers

depending on account of resource availability.

The sensitivity analysis results showed a similar trend to that observed in Fig 1, with Intervention 3 (twice-weekly and daily

staff testing) consistently averting the highest number of cases and deaths compared to lower testing frequencies and the

staff-only intervention. The epidemiological impact decreased with reduced test sensitivity (up to 13% fewer cases and

27% fewer deaths averted for daily testing combined with public health and social measures). Although significant

epidemiological impact was observed even at test sensitivities between 68% and 76%, these findings demonstrate the

importance of using high-sensitivity tests. Test sensitivity also significantly influenced the cost-effectiveness of

interventions. While three interventions were cost-saving under the assumption of perfect test sensitivity, this number

decreased to two when sensitivity was reduced. Twice-weekly testing combined with public health and social measures,

which appeared potentially cost-saving under perfect test sensitivity assumptions, was not cost-saving in the sensitivity

analysis. These findings highlight the influence of test sensitivity on both epidemiological outcomes and economic

evaluations. Further details are provided in the Supplementary Appendix.

Table 2: Interventions and associated costs

Table 2 displays hospitalisation, intervention and total costs for all interventions, including baseline. Intervention costs

comprise LFT tests, staff sick pay and backfill. Hospitalisation costs comprise non-critical and critical care. Intervention

and hospitalisation costs are combined to give an overall cost for each intervention and are compared to the baseline. All

costs are in 2022-23 millions of pounds (£).

Intervention	Intervention costs (£ million)	Hospitalisation costs (£ million)	Total costs (£ million)	Costs averted (baseline costs minus intervention costs) (£ million)
Baseline testing	2.0 (95% UI: 1.7; 2.5)	36.2 (95% UI: 29.9; 44.1)	38.2 (95% UI: 31.6; 46.4)	
Once a month testing	2.8 (95% UI: 2.3; 3.4)	36.1 (95% UI: 29.8; 44.0)	38.9 (95% UI: 32.2; 47.3)	-0.7 (95% UI: -0.9; -0.6)
Twice a month testing	4.5 (95% UI: 3.7; 5.5)	35.9 (95% UI: 29.6; 43.8)	40.4 (95% UI: 33.5; 49.0)	-2.2 (95% UI: -2.7; -1.8)

Once a week testing	6.9 (95% UI: 5.8; 8.3)	35.7 (95% UI: 29.4; 43.4)	42.6 (95% UI: 35.3; 51.6)	-4.3 (95% UI: -5.2; -3.7)
Twice a week testing	10.4 (95% UI: 9.0; 12.0)	35.3 (95% UI: 29.1; 43.1)	45.7 (95% UI: 38.2; 55.0)	-7.5 (95% UI: -8.6; -6.6)
Daily testing	24.4 (95% UI: 22.7; 26.5)	34.9 (95% UI: 28.7; 42.5)	59.2 (95% UI: 51.5; 68.8)	-21.0 (95% UI: -22.4; -19.9)
Baseline testing with public health and social measure	2.0(95% UI: 1.7; 2.5)	33.6 (95% UI: 27.5; 41.2)	35.6 (95% UI: 29.1; 43.5)	2.7 (95% UI: 2.0; 3.4)
Once a month testing with public health and social measure	2.8 (95% UI: 2.3; 3.4)	33.1 (95% UI: 27.0; 40.7)	35.9 (95% UI: 29.4; 44.1)	2.3 (95% UI: 1.5; 3.1)
Twice a month testing with public	4.5 (95% UI: 3.7; 5.5)	32.0 (95% UI: 26.0; 39.4)	36.5 (95% UI: 29.9; 45.0)	1.7 (95% UI: 0.7; 2.7)

health and social measure			
Once a week testing with public health and social measure	6.9 (95% UI: 5.8; 8.3)	30.0 (95% UI: 24.1; 37.2)	36.9 (95% UI: 30.2; 45.6)	1.3 (95% UI: -0.07; 2.7)
Twice a week testing with public health and social measure	10.4 (95% UI: 9.0; 12.0)	26.6 (95% UI: 21.2; 33.6)	37.0 (95% UI: 30.4; 45.6)	1.2 (95% UI: -0.5; 2.9)
Daily testing with public health and social measure	24.4 (95% UI: 22.7; 26.5)	16.9 (95% UI: 12.9; 22.2)	41.2 (95% UI: 35.7; 48.5)	-3.0 (95% UI: -5.4; 0.3)

Fig 2 presents the cost-effectiveness plane for the various intervention strategies. Interventions 2 and 3 are shown to be

less costly in most instances and successful at averting resident cases. However, daily testing under intervention 3,

despite averting a significant number of resident cases, may result in higher costs than the baseline scenario.

Fig 2: Cost-effectiveness plane as Incremental costs per COVID-19 cases averted over 12 months. Health

outcomes (resident cases averted) are plotted on the X axis and incremental costs in millions (£) are plotted on the Y axis.

Each point represents incremental costs over cases averted for each model run compared to the baseline scenario.

Interventions 2 and 3 (with monthly, twice a month, weekly and twice a week testing) are cost-saving in most cases and

always cost-effective. The cost-effectiveness of Intervention 3 with daily testing, however, depends on resource

availability.

Discussion

We presented a compartmental model simulating SARS-CoV-2 transmission in care homes for older adults in England to

ascertain the impact of staff testing interventions on resident cases and deaths. We further explored the associated costs

for each intervention to provide policy makers with grounded evidence to aid their decision-making for future pandemics.

The results of the study demonstrate that staff testing alone is not enough to evidence any substantial reductions in cases

and deaths in the resident population. Daily testing without a public health and social measures averted only 3.8%

(95%UI: 3.1-4.5%) cases and 3.5% (95%UI: 2.3-4.4%) deaths when compared to baseline. However, regular staff testing,

when paired with public health and social measures such as resident zoning, using PPE, contact tracing or improved

room ventilation, is the most effective strategy for reducing resident cases and deaths. Our results showed that during the

early phase of a pandemic (emerging virus, no prior immunity, no vaccination) 26.6% (95%UI: 23.2-30.4%) resident cases

and 25% (95%UI: 14.2-30.7%) resident deaths could be averted with twice-weekly testing of staff and 53.6% (95%UI:

49.5-57.7%) resident cases and 49.9% (95%UI: 26.3-59.1%) resident deaths with daily testing, combined with a

hypothetical public health and social measure that prevents transmission among residents. Furthermore, monthly, twice-

monthly, weekly and twice-weekly testing, when combined with public health and social measures, are cost-effective and

most likely cost-saving interventions, and can lead to up to ~£3.4 million costs saved compared to baseline over 12

months. These cost savings are due to a consistent reduction in hospitalisations in residents. On the other hand, daily

testing combined with public health and social measures is a costly intervention, where the high cost of frequent testing

appears to outweigh the financial benefits from fewer hospitalisations (up to £5.3 million additional costs compared to

baseline). However, due to the high number of cases and deaths that this intervention can avert, we cannot make

definitive conclusions on its cost-effectiveness, and any policy decisions should take resource availability into account.

Our epidemiological results align with several other studies, which suggest public health and social measures—such as

personal protective equipment (PPE), zoning of symptomatic cases, and improved room ventilation—can be used

alongside staff testing to maximise the prevention of cases and deaths[3-4]Click or tap here to enter text.. It is crucial to

carefully consider the type of public health and social measure implemented in conjunction with staff testing to ensure

residents' well-being is respected. Zoning within care homes may offer a practical solution for containing infections;

however, its effectiveness will depend on factors such as the facility's layout and available staff. While our findings

emphasise the importance of public health and social measures alongside staff testing in reducing infections, future

guidelines must also prioritise compassion. Full resident isolation is unlikely to be the optimal approach moving forward.

Our epidemiological results also differ from studies such as McGarry et al. (2023) [16] who demonstrated that increased

surveillance testing of staff members was associated with meaningful reductions in COVID-19 cases and deaths among

residents- especially before vaccine availability.

When it comes to the frequency of testing, our results align with the findings of Gómez Vázquez et al. [5] who also

modelled testing interventions in care homes and reported that increasing testing frequency to every three days led to a

significant reduction in infections and hospitalisations. On the other Hand, Nguyen et al.[4], recommend staff testing be

carried out every 7 to 10 days, explaining that although more frequent testing intervals result in improved outcomes, this

may be costly and not feasible. Whilst our results do show daily testing may be more costly than the baseline scenario, we

also illustrated how twice-weekly testing may be cost-saving and always cost-effective. Additionally, while more frequent

testing could increase workload, time pressures and discomfort associated with testing, our study has factored in the

sickness pay and backfill costs for staff required to isolate. This demonstrates that it is economically feasible to test as

frequently as twice-weekly, although it is important to note that the costs of testing, backfill and sickness pay were borne

by the government rather than care providers during the COVID-19 pandemic.

Our model has several strengths. This is the first study able to estimate the cost per case averted of different testing

scenarios, which is important from a policy-making perspective. Additionally, our analysis is grounded in real data, having

parametrised the model using actual rates of COVID-19 in care homes for older adults in England as observed during the

VIVALDI study [7] in 2021-2022. At the same time, the scenario and sensitivity analyses allow us to look beyond the case

of COVID19 and make our results informative for future pandemics.

Our study also has several limitations. Firstly, due to lack of available data, we could only consider a hypothetical public

health and social measure and were not able to explore specific interventions aimed at reducing transmission among

residents, such as partial or total resident zoning, resident testing, the use of face masks, or improved room ventilation.

This affects both our epidemiological and economic results as we could not consider the costs of these interventions

which should be explored in future research. We were, however, able to estimate thresholds on the maximum cost these

public health and social measures should have for the combined testing plus public health and social measure strategies

to be cost saving. Furthermore, due to the lack of available data, we parameterised the model with transmission rates

during the beginning of the vaccination campaign- despite focusing our work on pre-vaccination. Our baseline is therefore

representative of the first stages of a vaccine campaign where 38.4% of the population had a first vaccine by the 18th of

March [17]. This will likely underestimate the impact of interventions before vaccinations are in place. Chen et al.

demonstrated that testing in care homes was highly cost-effective - 3.5 times more cost-effective prior to vaccination

rollout [18].

Secondly, because our goal was to study a best-case scenario in order to estimate the maximum possible impact of

testing strategies, we assumed perfect sensitivity. However, to address real-world conditions, we also conducted a

sensitivity analysis (see Supplementary Appendix) using the actual sensitivity of LFT tests. This analysis demonstrated

that each intervention prevents fewer cases and deaths and is less cost-effective under realistic conditions. These

findings illustrate the importance of developing high-sensitivity tests to maximise epidemiological and economic outcomes.

Finally, our model was designed to represent an emergency scenario during the first stages of a new pandemic or a new

viral strain of an existing infection. For this reason we made some strong assumptions: (i) we did not include visits from

relatives or health professionals in our model. This may not be the case in future pandemic as more recent guidance set

out by the UKHSA reinforces the importance of allowing care home residents contacts with friends and relatives [19] Our

assumption is however supported by Rosello et al. [3] who estimated the importation of SARS-CoV-2 by visitors to be

negligible. (ii) We also assumed that contact patterns between staff and residents remained constant throughout the

simulation, but these patterns may change during an outbreak. (iii) We assumed no vaccine protection.

Assuming no protection from vaccination is reasonable in the context of care homes' preparedness to future pandemics.

However, to inform the management of COVID-19 and other infections for which vaccines are already available, it would

now be beneficial to revisit these findings under varying levels of vaccine protection to assess whether testing frequencies

should be adjusted in the context of vaccination. Several studies, including Fosdick et al. [20] and Vilches et al. [21]

demonstrated how effective vaccines could be with low testing rates, while Kahn et al. [22] emphasised that vaccines with

lower efficacy should be paired with more frequent testing, particularly in the context of waning immunity/need for re-

vaccination. Exploring this further—particularly with the economic component of our analysis—could offer valuable

insights. Future research could investigate different vaccine efficacies and the corresponding testing rates required, while

incorporating the economic considerations that are central to policy decision-making.

Conclusion

The study demonstrates the importance of combining staff testing with public health and social measures in order to

reduce cases and deaths in care homes. Frequent asymptomatic staff testing alone has limited impact in reducing

resident cases and deaths and is expensive; yet, combined with low-cost and highly effective public health and social

measures, it can significantly improve epidemiological outcomes and yield substantial cost savings. Daily testing is the

most effective in averting resident cases but may also result in higher costs, highlighting the balance needed between

improved health outcomes and the associated financial costs. Biweekly staff testing seems to be the most effective while

still being potentially cost saving. Asymptomatic staff testing, combined with public health and social measures was also

shown to be superior to public health and social measures with baseline symptomatic testing, demonstrating the

importance of testing. It is important to note, however, that decisions around cost effectiveness of testing may change

depending on the pathogen. For instance, with a less virulent pathogen, the resulting low rates of hospital admissions may

render frequent testing economically unfeasible, or vice versa, worse pathogens that resulted in higher rates of hospital

admissions would make the testing interventions here explored even more cost-effective. Despite this, these findings are

critical for guiding the rapid implementation of testing strategies, sick pay policies, and agency backfill measures in future

public health response. Policy makers must consider the incremental costs associated with each intervention against the

reduction of cases and deaths each offers, as well as the availability of resources when preparing for future epidemics

and pandemics in care home settings. Furthermore, the challenges surrounding funding for staff testing, sick pay, and

backfill due to increased testing and the inclusion of public health and social measures will need to be addressed,

including determining whether the responsibility lies with care providers, the NHS, or the Government.

Reference List

1.   Office for National Statistics. Older people living in care homes in 2021 and changes since 2011. 2023.

2.   Office for National Statistics. Deaths involving COVID-19 in the care sector, England and Wales: deaths registered
between week ending 20 March 2020 and week ending 2 April 2021. 2021.

3.   Rosello A, Barnard RC, Smith DRM, Evans S, Grimm F, Davies NG, et al. Impact of non-pharmaceutical
interventions on SARS-CoV-2 outbreaks in English care homes: a modelling study. BMC Infect Dis. 2022 Dec
1;22(1):324.

4.   Nguyen LKN, Howick S, McLafferty D, Anderson GH, Pravinkumar SJ, Van Der Meer R, et al. Evaluating
intervention strategies in controlling coronavirus disease 2019 (COVID-19) spread in care homes: An agent-based
model. Infect Control Hosp Epidemiol. 2021 Sep 14;42(9):1060–70.

5.   Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L, Cipriano LE, Langley JM, et al. Multifaceted strategies for the
control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Prev Med (Baltim). 2021
Jul;148:106564.

6.   Krutikov M, Bone D, Stirrup O, Bruton R, Azmi B, Fuller C, et al. VIVALDI Cohort Profile: Using linked, routinely
collected data and longitudinal blood sampling to characterise COVID-19 infections, vaccinations, and related
outcomes in care home staff and residents in England. Wellcome Open Res. 2024 Aug 19;8:553.

7.   Scarponi D, Iskauskas A, Clark RA, Vernon I, McKinley TJ, Goldstein M, et al. Demonstrating multi-country
calibration of a tuberculosis model using new history matching and emulation package - hmer. Epidemics. 2023
Jun;43:100678.

8.   Iskauskas A, Vernon I, Goldstein M, Scarponi D, McKinley TJ, White RG, et al. Emulation and History Matching
using the hmer Package. 2022 Sep 12;

9.   UK Health Security Agency. 2022. REACT-1 studies: monthly results.

10.   Webster HH, Nyberg T, Sinnathamby MA, Aziz NA, Ferguson N, Seghezzo G, et al. Hospitalisation and mortality
risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nat Commun. 2022 Oct
13;13(1):6053.

11.   Adams N, Stirrup O, Blackstone J, Krutikov M, Cassell JA, Cadar D, et al. Shaping care home COVID-19 testing
policy: a protocol for a pragmatic cluster randomised controlled trial of asymptomatic testing compared with
standard care in care home staff (VIVALDI-CT). BMJ Open. 2023 Nov 14;13(11):e076210.

12.   UKHSA. Personal Communication.

13.   Ferguson N, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and
healthcare demand. 2020.

14.   National Institute for Health and Care Excellence. Multiple Technology Appraisal Therapeutics for people with
COVID-19 [ID4038]. 2023.

15.   Krishnamoorthy A, Chandrapalan S, JalayeriNia G, Hussain Y, Bannaga A, Lei II, et al. Influence of seasonal and
operator variations on diagnostic accuracy of lateral flow devices during the COVID-19 pandemic: a systematic
review and meta-analysis. Clinical Medicine. 2023 Mar;23(2):144–50.

16.   McGarry BE, Gandhi AD, Barnett ML. Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes.
New England Journal of Medicine. 2023 Mar 23;388(12):1101–10.

17.   Gómez Vázquez JP, García YE, Schmidt AJ, Martínez-López B, Nuño M. Testing and vaccination to reduce the
impact of COVID-19 in nursing homes: an agent-based approach. BMC Infect Dis. 2022 Dec 19;22(1):477.

18.   GOV.UK. Vaccine update: issue 318, March 2021. 2021.

19.   Chen S, Creswell R, Hounsell R, Cantrell L, Bajaj S, Dahal P, et al. Mass testing for discovery and control of
COVID-19 outbreaks in adult social care: an observational study and cost-effectiveness analysis of 14 805 care
homes in England. BMJ Public Health. 2025 Jan 28;3(1):e001376.

20.   UK Health Security Agency. Supporting safer visiting in care homes during infectious illness outbreaks. 2024.

21.   Fosdick BK, Bayham J, Dilliott J, Ebel GD, Ehrhart N. Model-based evaluation of policy impacts and the continued
COVID-19 risk at long term care facilities. Infect Dis Model. 2022 Sep;7(3):463–72.

22.   Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L, Cipriano LE, Langley JM, et al. Multifaceted strategies for the
389   control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. Prev Med (Baltim). 2021
390   Jul;148:106564.

391   23.   Kahn R, Holmdahl I, Reddy S, Jernigan J, Mina MJ, Slayton RB. Mathematical Modeling to Inform Vaccination
392   Strategies and Testing Approaches for Coronavirus Disease 2019 (COVID-19) in Nursing Homes. Clinical Infectious
393   Diseases. 2022 Mar 1;74(4):597–603.

Fig1

Fig2